You have free access to this content

Cancer

Cover image for Vol. 118 Issue 13

1 July 2012

Volume 118, Issue 13

Pages 3223–3446

  1. CancerScope

    1. Top of page
    2. CancerScope
    3. Editorials
    4. Original Articles
    5. Erratum
    1. You have free access to this content
    2. You have free access to this content
    3. You have free access to this content
    4. You have free access to this content
  2. Editorials

    1. Top of page
    2. CancerScope
    3. Editorials
    4. Original Articles
    5. Erratum
    1. You have free access to this content
      Pregnancy-associated breast cancer : An entity needing refinement of the definition (pages 3226–3228)

      Virginia F. Borges and Pepper J. Schedin

      Article first published online: 15 NOV 2011 | DOI: 10.1002/cncr.26643

      Pregnancy-associated breast cancer is an important but challenging topic of research. The article by Murphy et al on this subject is reviewed, and includes a discussion of the definition of pregnancy-associated breast cancer, in terms of whether diagnosis is made during or after pregnancy.

    2. You have free access to this content
      Which is the best foot to put forward in recurrent ovarian cancer? (pages 3229–3231)

      Peter G. Rose

      Article first published online: 9 NOV 2011 | DOI: 10.1002/cncr.26615

      This investigation of sequential versus combination chemotherapy for platinum-sensitive, recurrent ovarian cancer uses a study design that involves giving sequential docetaxel followed by carboplatin. On the basis of the improved progression-free rate with the combination, use of a nonplatinum agent as the first of the sequential therapies in a platinum-sensitive patient may not be putting the best foot forward.

    3. You have free access to this content
      Androgen deprivation for prostate cancer : The case for “first, do no harm” (pages 3232–3235)

      Vahakn B. Shahinian

      Article first published online: 9 NOV 2011 | DOI: 10.1002/cncr.26624

      The list of adverse consequences of androgen deprivation therapy for prostate cancer continues to grow, with the latest addition being an increased risk of thromboembolism. Accordingly, use of androgen deprivation therapy should be restricted to settings where clear evidence of benefit exists.

  3. Original Articles

    1. Top of page
    2. CancerScope
    3. Editorials
    4. Original Articles
    5. Erratum
    1. Disease Site

      Breast Disease
      You have free access to this content
      Prognostic value of positive human epidermal growth factor receptor 2 status and negative hormone status in patients with T1a/T1b, lymph node-negative breast cancer (pages 3236–3243)

      Lorenzo Livi, Icro Meattini, Calogero Saieva, Ciro Franzese, Vanessa Di Cataldo, Daniela Greto, Davide Franceschini, Vieri Scotti, Pierluigi Bonomo, Jacopo Nori, Luis Sanchez, Vania Vezzosi, Simonetta Bianchi, Luigi Cataliotti and Giampaolo Biti

      Article first published online: 25 OCT 2011 | DOI: 10.1002/cncr.26647

      Patients with small, lymph node-negative breast cancer have a low risk of distant and local recurrence; however, younger age is a significant risk factor for the occurrence of such events. Young women with positive human epidermal growth factor receptor 2 (HER2) status and negative hormone receptor status have a significant risk of distant recurrence and should be considered for anti-HER2 adjuvant therapy.

    2. You have free access to this content
      Randomized double-blind phase 2 trial of 3 doses of TAS-108 in patients with advanced or metastatic postmenopausal breast cancer (pages 3244–3253)

      Aman Buzdar, Charles Vogel, Lee Schwartzberg, August Garin, Alejandra Perez, James Ingle, Michele Houghton, Christopher Zergebel and Bill Kimball

      Article first published online: 1 NOV 2011 | DOI: 10.1002/cncr.26419

      TAS-108, an antiestrogen, evaluated in metastatic breast cancer, demonstrates significant antitumor activity. Because of the superior safety profile, TAS-108 40 mg daily is recommended for further development.

    3. You have free access to this content
      Current or recent pregnancy is associated with adverse pathologic features but not impaired survival in early breast cancer (pages 3254–3259)

      Conleth G. Murphy, Divya Mallam, Samantha Stein, Sujata Patil, Jane Howard, Nancy Sklarin, Clifford A. Hudis, Mary L. Gemignani and Andrew D. Seidman

      Article first published online: 15 NOV 2011 | DOI: 10.1002/cncr.26654

      We compared the clinical features and survival of 99 women diagnosed with pregnancy-associated breast cancer (PABC) and 186 control patients matched for age and year of diagnosis. Although PABC was associated with more adverse pathologic features, the diagnosis of PABC was not itself an independent adverse prognostic feature.

    4. Endocrine Disease
      You have free access to this content
      Insular thyroid cancer : A population-level analysis of patient characteristics and predictors of survival (pages 3260–3267)

      Hadiza S. Kazaure, Sanziana A. Roman and Julie A. Sosa

      Article first published online: 17 JAN 2012 | DOI: 10.1002/cncr.26638

      Insular thyroid cancer is rare and aggressive. Its management should include total thyroidectomy and high-dose radioiodine for all patients and appropriate neck dissections for patients with lymph node disease.

    5. Gastrointestinal Disease
      You have free access to this content
      Effect of histologic subtype on treatment and outcomes for esophageal cancer in the United States (pages 3268–3276)

      Ryan P. Merkow, Karl Y. Bilimoria, Martin D. McCarter, Warren B. Chow, Howard S. Gordon, Andrew K. Stewart, Clifford Y. Ko and David J. Bentrem

      Article first published online: 17 OCT 2011 | DOI: 10.1002/cncr.26608

      It is unclear whether esophageal cancer treatment patterns differ by tumor histology in the United States. Our analysis demonstrates that a large proportion of patients are being treated nonoperatively, and the likelihood of surgical treatment for nonmetastatic disease was significantly lower in patients with squamous cell cancer compared with patients with adenocarcinoma, even at high-volume academic cancer centers.

    6. Genitourinary Disease
      You have free access to this content
      Cessation of vascular endothelial growth factor–targeted therapy in patients with metastatic renal cell carcinoma : Feasibility and clinical outcome (pages 3277–3282)

      Sarmad Sadeghi, Laurence Albiges, Laura S. Wood, Shari L. Black, Timothy D. Gilligan, Robert Dreicer, Jorge A. Garcia, Bernard J. Escudier and Brian I. Rini

      Article first published online: 2 DEC 2011 | DOI: 10.1002/cncr.26666

      A select subset of patients with metastatic renal cell carcinoma who achieved stable disease or better on vascular endothelial growth factor–targeted therapy can be observed off all therapy. Further prospective investigation is warranted.

      Corrected by:

      Erratum: Erratum

      Vol. 118, Issue 21, 5448, Article first published online: 17 APR 2012

    7. Gynecologic Oncology
      You have free access to this content
      A multicenter, randomized, phase 2 clinical trial to evaluate the efficacy and safety of combination docetaxel and carboplatin and sequential therapy with docetaxel then carboplatin in patients with recurrent platinum-sensitive ovarian cancer (pages 3283–3293)

      Angeles Alvarez Secord, Andrew Berchuck, Robert V. Higgins, Lawrence R. Nycum, Matthew F. Kohler, Larry E. Puls, Robert W. Holloway, George S. Lewandowski, Fidel A. Valea and Laura J. Havrilesky

      Article first published online: 9 NOV 2011 | DOI: 10.1002/cncr.26610

      Both combination and sequential weekly docetaxel and carboplatin have activity in recurrent platinum-sensitive epithelial ovarian cancer with acceptable toxicity profiles.

    8. Hematologic Malignancies
      You have free access to this content
      Phase 2 trial of “Sandwich” L-asparaginase, vincristine, and prednisone chemotherapy with radiotherapy in newly diagnosed, stage IE to IIE, nasal type, extranodal natural killer/T-cell lymphoma (pages 3294–3301)

      Ming Jiang, Hong Zhang, Yu Jiang, Qunpei Yang, Li Xie, Weiping Liu, Wenyan Zhang, Xiaohui Ji, Ping Li, Nianyong Chen, Sha Zhao, Feng Wang and Liqun Zou

      Article first published online: 2 DEC 2011 | DOI: 10.1002/cncr.26629

      This study is the first prospective study of “sandwich” L-asparaginase, vincristine, and prednisone (LVP) and radiotherapy for untreated, localized nasal natural killer/T-cell lymphoma. This treatment protocol produced a significant, short-time curative rate and was generally well tolerated, with particularly mild hematologic side effects.

    9. Hepatobiliary Disease
      You have free access to this content
      Therapeutic efficacy of combination therapy with intra-arterial 5-fluorouracil and systemic pegylated interferon α-2b for advanced hepatocellular carcinoma with portal venous invasion (pages 3302–3310)

      Kazuhiro Kasai, Akira Ushio, Yukiho Kasai, Kei Sawara, Yasuhiro Miyamoto, Kanta Oikawa, Hidekatsu Kuroda, Yasuhiro Takikawa and Kazuyuki Suzuki

      Article first published online: 9 NOV 2011 | DOI: 10.1002/cncr.26648

      The present study demonstrates the efficacy of hepatic arterial infusion chemotherapy (HAIC) with pegylated interferon α-2b and 5-fluorouracil for advanced hepatocellular carcinoma (HCC) patients. This newly developed combination therapy is likely to be useful for patients with advanced HCC, although a large-scale randomized controlled study in comparison with sorafenib or HAIC with other regimens is needed to properly evaluate the efficacy of this therapy.

    10. Skin
      You have free access to this content
      Recurrence after complete resection and selective use of adjuvant therapy for stage I through III Merkel cell carcinoma (pages 3311–3320)

      Ryan C. Fields, Klaus J. Busam, Joanne F. Chou, Katherine S. Panageas, Melissa P. Pulitzer, Peter J. Allen, Dennis H. Kraus, Mary S. Brady and Daniel G. Coit

      Article first published online: 9 NOV 2011 | DOI: 10.1002/cncr.26626

      Merkel cell carcinoma (MCC) is a rare cutaneous neuroendocrine neoplasm with a propensity for lymphatic and distant spread. Adjuvant treatment after curative surgery is controversial. The authors present the largest series to date of adjuvant treatment and recurrence after treatment for stage I through III MCC.

    11. Soft Tissue and Bone Sarcoma
      You have free access to this content
      Prognosis for primary retroperitoneal sarcoma survivors : A conditional survival analysis (pages 3321–3329)

      Andrea M. Abbott, Elizabeth B. Habermann, Helen M. Parsons, Todd Tuttle and Waddah Al-Refaie

      Article first published online: 13 JAN 2012 | DOI: 10.1002/cncr.26665

      This population-based study demonstrates that the ability of the current American Joint Committee on Cancer staging system to predict conditional survival in patients with retroperitoneal sarcoma dampens 1 year after diagnosis; only tumor grade remains significant. Conditional survival estimates allow clinicians to provide survivors with more meaningful prognostic estimates.

    12. You have free access to this content
      Comparison of doxorubicin and weekly paclitaxel efficacy in metastatic angiosarcomas (pages 3330–3336)

      Antoine Italiano, Angela Cioffi, Nicolas Penel, Matteo Giaj Levra, Corinne Delcambre, Elsa Kalbacher, Christine Chevreau, François Bertucci, Nicolas Isambert, Jean-Yves Blay, Binh Bui, Cristina Antonescu, David R. D'Adamo, Robert G. Maki and Mary Louise Keohan

      Article first published online: 1 NOV 2011 | DOI: 10.1002/cncr.26599

      Single-agent doxorubicin is still considered the first-line standard treatment for patients with metastatic soft-tissue sarcoma (STS). However, several studies have shown that paclitaxel, a drug considered inactive against STS, has significant activity in angiosarcomas, particularly when administered in a weekly schedule. The results of this study show that angiosarcomas are at least initially chemosensitive, and indicate that doxorubicin and weekly paclitaxel appear largely equivalent in terms of efficacy in the first-line setting.

    13. Discipline

      Complementary Medicine
      You have free access to this content
      Randomized controlled trial of acupuncture for prevention of radiation-induced xerostomia among patients with nasopharyngeal carcinoma (pages 3337–3344)

      Zhiqiang Meng, M. Kay Garcia, Chaosu Hu, Joseph Chiang, Mark Chambers, David I. Rosenthal, Huiting Peng, Ying Zhang, Qi Zhao, Genming Zhao, Luming Liu, Amy Spelman, J. Lynn Palmer, Qi Wei and Lorenzo Cohen

      Article first published online: 9 NOV 2011 | DOI: 10.1002/cncr.26550

      The authors conducted a randomized, clinical trial of acupuncture to decrease the development of xerostomia in patients undergoing radiation for nasopharyngeal carcinoma. Acupuncture given concurrently with radiotherapy significantly reduces xerostomia and improves quality of life during radiotherapy and 1 and 6 months later.

    14. Disparities Research
      You have free access to this content
      Reasons for underuse of recommended therapies for colorectal and lung cancer in the Veterans Health Administration (pages 3345–3355)

      Mary Beth Landrum, Nancy L. Keating, Elizabeth B. Lamont, Samuel R. Bozeman and Barbara J. McNeil

      Article first published online: 9 NOV 2011 | DOI: 10.1002/cncr.26628

      Physicians' recommendations against treatments for patients in poor health and patients' refusal of therapy are the largest contributors to lack of treatment and disparities in use. These findings have important implications for the design of policies to eliminate disparities in cancer care and highlight the need for additional evidence on the effectiveness of common therapies in community-based populations not typically enrolled in clinical trials.

    15. Epidemiology
      You have free access to this content
      Genetic polymorphisms in obesity-related genes and endometrial cancer risk (pages 3356–3364)

      Xiaoli Chen, Yong-Bing Xiang, Ji-Rong Long, Hui Cai, Qiuyin Cai, Jiarong Cheng, Wanqing Wen, Yu-Tang Gao, Wei Zheng and Xiao-Ou Shu

      Article first published online: 28 OCT 2011 | DOI: 10.1002/cncr.26552

      A large population-based case-control study finds that genetic polymorphisms in the ADIPOQ genes are associated with endometrial cancer risk and obesity.

    16. Medical Oncology
      You have free access to this content
      MicroRNA-200b reverses chemoresistance of docetaxel-resistant human lung adenocarcinoma cells by targeting E2F3 (pages 3365–3376)

      Bing Feng, Rui Wang, Hai-Zhu Song and Long-Bang Chen

      Article first published online: 2 DEC 2011 | DOI: 10.1002/cncr.26560

      Down-regulation of microRNA-200b contributes to chemoresistance of human lung adenocarcinoma cells to docetaxel. This process is mediated at least partially by targeting E2F3, which is critical for the maintenance of normal cell cycle progression.

    17. You have free access to this content
      Predicting the risk of chemotherapy toxicity in older patients: The Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score (pages 3377–3386)

      Martine Extermann, Ivette Boler, Richard R. Reich, Gary H. Lyman, Richard H. Brown, Joseph DeFelice, Richard M. Levine, Eric T. Lubiner, Pablo Reyes, Frederic J. Schreiber III and Lodovico Balducci

      Article first published online: 9 NOV 2011 | DOI: 10.1002/cncr.26646

      Having a tool to help predict an older cancer patient's risk of severe side effects from chemotherapy could be very helpful for treatment planning. The authors develop the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score in a prospective multicentric study to address this need.

    18. You have free access to this content
      The molecular role of Fra-1 and its prognostic significance in human esophageal squamous cell carcinoma (pages 3387–3396)

      Akihiro Usui, Isamu Hoshino, Yasunori Akutsu, Haruhito Sakata, Takanori Nishimori, Kentaro Murakami, Masayuki Kano, Kiyohiko Shuto and Hisahiro Matsubara

      Article first published online: 25 OCT 2011 | DOI: 10.1002/cncr.26652

      Fra-1 is overexpressed in a variety of human tumors, including esophageal squamous cell carcinoma, and is known to up-regulate the expression of genes involved in tumor progression and invasion. The authors' results suggest that down-regulation of Fra-1 may represent a therapeutic approach to the development of antitumoral agents for those highly malignant tumors known to express Fra-1.

    19. Outcomes Research
      You have free access to this content
      Androgen deprivation and thromboembolic events in men with prostate cancer (pages 3397–3406)

      Behfar Ehdaie, Coral L. Atoria, Amit Gupta, Andrew Feifer, William T. Lowrance, Michael J. Morris, Peter T. Scardino, James A. Eastham and Elena B. Elkin

      Article first published online: 9 NOV 2011 | DOI: 10.1002/cncr.26623

      In a population-based cohort, androgen deprivation therapy was associated with an increased risk of thromboembolic events. For men initiated on androgen deprivation therapy, they and their physicians should be aware and vigilant for thromboembolic complications.

    20. You have free access to this content
      Clinical predictors of cognitive function in adults treated with hematopoietic cell transplantation (pages 3407–3416)

      Heather S. L. Jim, Brent Small, Sheri Hartman, Jamie Franzen, Shannon Millay, Kristin Phillips, Paul B. Jacobsen, Margaret Booth-Jones and Joseph Pidala

      Article first published online: 2 DEC 2011 | DOI: 10.1002/cncr.26645

      Recovery of cognitive function after hematopoietic cell transplantation is predicted by cumulative clinical risk of pretransplantation neuropsychological risk factors, transplantation-specific factors, and post-transplantation complications. Patients with a complicated clinical course should be referred for evaluation and management of cognitive deficits.

    21. Psychosocial Oncology
      You have free access to this content
      When parents disclose BRCA1/2 test results: Their communication and perceptions of offspring response (pages 3417–3425)

      Angela R. Bradbury, Linda Patrick-Miller, Brian L. Egleston, Olufunmilayo I. Olopade, Mary B. Daly, Cynthia W. Moore, Colleen B. Sands, Helen Schmidheiser, Preethi K. Kondamudi, Maia Feigon, Comfort N. Ibe and Christopher K. Daugherty

      Article first published online: 9 JAN 2012 | DOI: 10.1002/cncr.26471

      Many parents communicate their BRCA1/2 test results to young offspring. Parents' perceptions of offspring responses appear to vary by offspring age and parent test result. A better understanding of how young offspring respond to information about hereditary risk for adult cancer could provide opportunities to optimize adaptive psychosocial responses to risk information and performance of health behaviors, in adolescence and throughout an at-risk life span.

    22. Translational Research
      You have free access to this content
      MicroRNA expression profiling is a potential diagnostic tool for thyroid cancer (pages 3426–3432)

      Menno R. Vriens, Julie Weng, Insoo Suh, Nhung Huynh, Marlon A. Guerrero, Wen T. Shen, Quan-Yang Duh, Orlo H. Clark and Electron Kebebew

      Article first published online: 17 OCT 2011 | DOI: 10.1002/cncr.26587

      This microRNA array-based analysis identified several putative markers that could distinguish benign from malignant thyroid neoplasms in both tissue and FNA samples.

    23. You have free access to this content
      Inhibition of the NADPH oxidase regulates heme oxygenase 1 expression in chronic myeloid leukemia (pages 3433–3445)

      Melissa M. Singh, Mary E. Irwin, Yin Gao, Kechen Ban, Ping Shi, Ralph B. Arlinghaus, Hesham M. Amin and Joya Chandra

      Article first published online: 2 DEC 2011 | DOI: 10.1002/cncr.26621

      Heme oxygenase 1 (HO-1) expression is increased in patients who have chronic myelogenous leukemia in blast crisis. The nicotinamide adenine dinucleotide phosphate oxidase (Nox) components Ras-related C3 botulinum toxin substrate 1 (Rac1) and the 47-kd cytosolic subunit of Nox (p47phox) regulate HO-1 protein expression.

  4. Erratum

    1. Top of page
    2. CancerScope
    3. Editorials
    4. Original Articles
    5. Erratum
    1. You have free access to this content

SEARCH

SEARCH BY CITATION